Patents by Inventor Peter J. Mohler

Peter J. Mohler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of detecting oxidized calcium/calmodulin dependent protein kinase II
    Patent number: 9090701
    Abstract: Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: July 28, 2015
    Assignee: University of Iowa Research Foundation
    Inventors: Mark E. Anderson, Peter J. Mohler, Douglas R. Spitz, Jr., Jeffrey Robert Erickson
  • Monoclonal antibodies specific for oxidized calcium/calmodulin dependent protein kinase II
    Patent number: 8841423
    Abstract: Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: September 23, 2014
    Assignee: University of Iowa Research Foundation
    Inventors: Mark E. Anderson, Peter J. Mohler, Douglas R. Spitz, Jr., Jeffrey Robert Erickson
  • Kits for Detecting Direct Oxidation of Calcium/Calmodulin Dependent Protein Kinase II and Associated Diagnostic and Therapeutic Methods
    Publication number: 20130012568
    Abstract: Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy.
    Type: Application
    Filed: September 6, 2012
    Publication date: January 10, 2013
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Mark E. Anderson, Peter J. Mohler, Douglas R. Spitz, JR., Jeffrey Robert Erickson
  • Direct Oxidation of Calcium/Calmodulin Dependent Protein Kinase II and Associated Diagnostic and Therapeutic Methods
    Publication number: 20100226929
    Abstract: Calcium/calmodulin dependent protein kinase II (CaMKII) has been found to be directly oxidized, and direct oxidation of CaMKII was observed to result in calcium independent activation of CaMKII. Antibodies that bind specifically to oxidized forms of CaMKII (oxCaMKII) were generated and were utilized to detect oxCaMKII in blood from: (1) mice with cancer; (2) mice with a knock out of the gene encoding methionine sulfoxide reductase; (3) mice injected with angiotensin II; (4) mice injected with bacterial endotoxin; (5) mice fed a pro-oxidant (ketogenic) diet; and (6) mice with cancer that had been treated with experimental therapy.
    Type: Application
    Filed: April 27, 2009
    Publication date: September 9, 2010
    Applicant: University of Iowa Research Foundation
    Inventors: Mark E. Anderson, Peter J. Mohler, Douglas R. Spitz, JR., Jeffrey Robert Erickson
  • Methods of modulating localization and physiological function of IP3 receptors
    Patent number: 7144706
    Abstract: The present invention relates, generally, to inositol 1,4,5-triphosphate receptors (IP3R), and, in particular, to methods of modulating the activity of 220 kDa ankyrin-B in cellular localization and physiological function of IP3R. The invention further relates to methods of identifying compounds suitable for use in such methods and to compounds so identified.
    Type: Grant
    Filed: January 3, 2003
    Date of Patent: December 5, 2006
    Assignee: Duke University
    Inventors: Vann Bennett, Anthony O. Gramolini, Peter J. Mohler
  • Methods of modulating localization and physiological function of IP3 receptors
    Publication number: 20030167491
    Abstract: The present invention relates, generally, to inositol 1,4,5-triphosphate receptors (IP3R), and, in particular, to methods of modulating the activity of 220 kDa ankyrin-B in cellular localization and physiological function of IP3R. The invention further relates to methods of identifying compounds suitable for use in such methods and to compounds so identified.
    Type: Application
    Filed: January 3, 2003
    Publication date: September 4, 2003
    Applicant: DUKE UNIVERSITY
    Inventors: Vann Bennett, Anthony O. Gramolini, Peter J. Mohler